BACKGROUND: The prognosis of esophageal cancer (EC) depends on the depth of tumor
invasion and lymph node metastasis. EC limited to the mucosa (T1a) can be treated …

Vascular endothelial growth factor (VEGF) targeted therapy, either alone or in combination
with chemotherapy, has become the standard of care in several solid tumours, including …

Gastric cancer is the third leading cause of cancer-related deaths worldwide. Over 95% of
gastric cancers are adenocarcinomas, which are typically classified based on anatomic …

Methods A taskforce was assembled through the Workforce on Evidence Based Surgery and
the General Thoracic Surgery Workforce of The Society of Thoracic Surgeons (STS) with …

Mice lacking the proto-oncogene c-fos develop the bone disease osteopetrosis. Fos mutant
mice were found to have a block in the differentiation of bone-resorbing osteoclasts that was …

Ipilimumab improves clinical outcomes when combined with nivolumab in metastatic non-small
cell lung cancer (NSCLC), but its efficacy and impact on the immune microenvironment …

Gastric cancer is the fifth most frequently diagnosed cancer and the third leading cause of
death from cancer in the world. Several advances have been made in the staging procedures, …

Methods: The Esophageal Complications Consensus Group comprised 21 high-volume
esophageal surgeons from 14 countries, supported by all the major thoracic and upper …

Esophageal cancer is the sixth leading cause of cancer-related deaths worldwide.
Squamous cell carcinoma is the most common histology in Eastern Europe and Asia, and …

Colony stimulating factor-1 (CSF-1) regulates the survival, proliferation and differentiation of
mononuclear phagocytes. The osteopetrotic (op/op) mutant mouse is devoid of CSF-1 due …